The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease

The journal of prevention of Alzheimer's disease

Volumn 4, Issue 4, 2017, Pages 242-246

  Lopez Lopez, C ^a   Caputo, A ^b   Liu, F ^b   Riviere, M E ^b   Rouzade Dominguez, M L ^b   Thomas, R G ^b   Langbaum, J B ^b   Lenz, R ^b   Reiman, E M ^b   Graf, A ^b   Tariot, P N ^b  

^a Neuroscience Development Unit   (Switzerland)

^b NONE

Author keywords

Alzheimer s disease; BACE inhibitor; generation program

Indexed keywords

APOLIPOPROTEIN E4; ENZYME INHIBITOR; SECRETASE;

AGE; ALZHEIMER DISEASE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE PREDISPOSITION; GENETICS; HUMAN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PUBLIC-PRIVATE PARTNERSHIP;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; APOLIPOPROTEIN E4; DISEASE SUSCEPTIBILITY; ENZYME INHIBITORS; HUMANS; PATIENT SELECTION; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 85050993485     PISSN: None     EISSN: 24260266     Source Type: Journal    
DOI: 10.14283/jpad.2017.37     Document Type: Article

References (0)